Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2011 2
2012 1
2013 4
2016 3
2017 4
2018 6
2019 5
2020 6
2021 12
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer.
Witlox WJA, Ramaekers BLT, Lacas B, Le Pechoux C, Sun A, Wang SY, Hu C, Redman M, van der Noort V, Li N, Guckenberger M, van Tinteren H, Hendriks LEL, Groen HJM, Joore MA, De Ruysscher DKM. Witlox WJA, et al. Among authors: ramaekers blt. Radiother Oncol. 2022 May;170:95-101. doi: 10.1016/j.radonc.2022.02.036. Epub 2022 Mar 5. Radiother Oncol. 2022. PMID: 35259416 Free article. Clinical Trial.
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
Claessens AKM, Busschbach JJV, Ramaekers BLT, Erdkamp FLG, Bouma JM, van Leeuwen-Stok AE, Tjan-Heijnen VCG, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: ramaekers blt. Acta Oncol. 2022 May;61(5):619-624. doi: 10.1080/0284186X.2022.2033832. Epub 2022 Feb 9. Acta Oncol. 2022. PMID: 35139727 No abstract available.
Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials.
Witlox WJA, Ramaekers BLT, Lacas B, Pechoux CL, Sun A, Wang SY, Hu C, Redman M, van der Noort V, Li N, Guckenberger M, van Tinteren H, Groen HJM, Joore MA, De Ruysscher DKM. Witlox WJA, et al. Among authors: ramaekers blt. Radiother Oncol. 2021 Nov;164:163-166. doi: 10.1016/j.radonc.2021.09.029. Epub 2021 Oct 4. Radiother Oncol. 2021. PMID: 34619235 Free article.
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
Simons MJHG, Retèl VP, Ramaekers BLT, Butter R, Mankor JM, Paats MS, Aerts JGJV, Mfumbilwa ZA, Roepman P, Coupé VMH, Uyl-de Groot CA, van Harten WH, Joore MA. Simons MJHG, et al. Among authors: ramaekers blt. Pharmacoeconomics. 2021 Dec;39(12):1429-1442. doi: 10.1007/s40273-021-01073-y. Epub 2021 Aug 18. Pharmacoeconomics. 2021. PMID: 34405371 Free PMC article.
Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases").
Grimm SE, Pouwels X, Ramaekers BLT, Wijnen B, Knies S, Grutters J, Joore MA. Grimm SE, et al. Among authors: ramaekers blt. Orphanet J Rare Dis. 2021 Jul 19;16(1):320. doi: 10.1186/s13023-021-01938-7. Orphanet J Rare Dis. 2021. PMID: 34281581 Free PMC article. No abstract available.
46 results